KalVista falls as Endpoints News reports FDA commissioner sought rejection of drug

Shares of drug developer KalVista Pharmaceuticals KALV.O fall 5.8% to $11.24

Endpoints News reports that "FDA Commissioner Marty Makary was behind a short-lived request last week to reject a rare disease drug application from KalVista Pharmaceuticals" citing multiple agency sources

"We are unaware of any internal deliberations at the FDA and we do not comment on rumors. We continue to have productive engagement with the FDA and remain focused on the goal of bringing this important new therapy to people living with HAE"- co said in am emailed response

The FDA earlier in June extended the review of KALV's drug for a type of hereditary swelling disorder due to heavy workload and limited resources

The FDA had indicated that it now expects to deliver a decision within four weeks

Including session moves, KALE up 38.4% YTD